QSAM Biosciences, Inc.
A408WA
Recommendation
--
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
--
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
--
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -37.31% | -51.53% | -49.47% | -56.26% | -57.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.81% | -40.48% | -39.63% | -49.81% | -50.54% |
| Operating Income | 27.81% | 40.48% | 39.63% | 49.81% | 50.54% |
| Income Before Tax | 19.85% | 35.78% | 33.39% | 44.44% | 54.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.85% | 35.78% | 33.39% | 44.44% | 54.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.85% | 35.78% | 33.39% | 44.44% | 54.24% |
| EBIT | 27.81% | 40.48% | 39.63% | 49.81% | 50.54% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
